Holen Sie sich die Stockscreener-App
4.20
7.49%
-0.34
Handel nachbörslich:
4.40
0.20
+4.76%
Schlusskurs vom Vortag:
$4.54
Offen:
$4.58
24-Stunden-Volumen:
216.31K
Relative Volume:
0.76
Marktkapitalisierung:
$91.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.87M
KGV:
-1.3089
EPS:
-3.2089
Netto-Cashflow:
$-61.75M
1W Leistung:
-3.89%
1M Leistung:
-22.08%
6M Leistung:
-56.57%
1J Leistung:
-60.00%
1-Tages-Spanne:
$4.025
$4.665
1-Wochen-Bereich:
$4.025
$4.80
52-Wochen-Spanne:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
4.20 | 99.05M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | Herabstufung | Stifel | Buy → Hold |
| 2026-01-28 | Eingeleitet | B. Riley Securities | Buy |
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-12 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-07 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - GlobeNewswire Inc.
AARD stock crashes 34% – here’s why this analyst finds it ‘hard to lean into’ Aardvark at this stage - MSN
Aardvark Therapeutics faces investigation after FDA halts its Phase 3 trial, causing stock to plunge. - Pluang
Aardvark Therapeutics shares plunge 56% after halting Phase 3 trial due to safety concerns. - Pluang
We're Keeping An Eye On Aardvark Therapeutics' (NASDAQ:AARD) Cash Burn Rate - Moomoo
FDA halts Aardvark Therapeutics rare disease study - MSN
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS - TradingView
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - PR Newswire
FDA halts Aardvark Therapeutics' ARD-101 trial over heart safety concerns, stock now valued mainly for cash. - Pluang
Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward (NASDAQ:AARD) - Seeking Alpha
AARD stock plummets after hours as cardiac safety concerns trigger FDA hold on late-stage program - MSN
FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4 - TipRanks
Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Sahm
Aardvark Therapeutics downgraded to Underperform from Buy at BofA - TipRanks
Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug - MedCity News
Aardvark Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.3, Implies 187% Upside - TradingView
B. Riley Adjusts Aardvark Therapeutics Price Target to $7 From $8, Maintains Buy Rating - Moomoo
Aardvark plummets on FDA clinical hold on Prader-Willi Syndrome asset - Seeking Alpha
Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application - Moomoo
AARD Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk - Moomoo
AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage - Stocktwits
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
FDA puts clinical hold on Aardvark’s IND - The Pharma Letter
Aardvark Therapeutics, Inc.Common Stock (Nasdaq:AARD) Stock Quote - The Chronicle-Journal
FDA Halts Aardvark Therapeutics Rare Disease Study - Benzinga
AARD Downgraded by Morgan Stanley -- Price Target Lowered to $3. - GuruFocus
FDA Places Full Hold On Aardvark’s ARD-101 Months After Voluntary Safety Pause - Citeline News & Insights
B. Riley Securities Maintains Aardvark Therapeutics(AARD.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
BTIG downgrades Aardvark Therapeutics stock rating on FDA hold By Investing.com - Investing.com Australia
Aardvark Therapeutics stock tumbles on FDA clinical hold, analyst downgrades - Investing.com Australia
BTIG downgrades Aardvark Therapeutics stock rating on FDA hold - Investing.com
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
AARD Stock Plummets 30.2% Amid U.S.-China Talks - GuruFocus
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
FDA hold puts Aardvark Prader-Willi drug in limbo - Yahoo Finance
Morgan Stanley Downgrades Aardvark Therapeutics(AARD.US) to Sell Rating, Cuts Target Price to $3 - Moomoo
Morgan Stanley downgrades Aardvark Therapeutics stock rating on FDA hold - Investing.com India
Morgan Stanley downgrades Aardvark Therapeutics stock rating on FDA hold By Investing.com - Investing.com Australia
Aardvark Therapeutics, Inc. Stock 12‑Month Price Target Cut to $18.45, Implies 174% Upside - TradingView
AARD Faces FDA Clinical Hold on ARD-101 Development - GuruFocus
FDA places full clinical hold on Aardvark’s drug for extreme hunger in Prader-Willi syndrome - WSAU
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
FDA Clinical Hold Halts Aardvark’s ARD-101 Late-Stage Program - TipRanks
FDA places clinical hold on Aardvark’s ARD-101 drug trials - Investing.com UK
FDA places clinical hold on Aardvark’s ARD-101 drug trials By Investing.com - Investing.com South Africa
FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome - Reuters
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aardvark Therapeutics Inc-Aktie (AARD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):